Applications of Boc-(R)-3-Amino-4-(4-Fluoro-Phenyl)-Butyric Acid in Industrial Manufacturing

As a specialist producer of Boc-(R)-3-Amino-4-(4-Fluoro-Phenyl)-Butyric Acid, we equip pharmaceutical and specialty chemical industries with high-purity intermediates for advanced synthesis. Below are the key industrial application scenarios where our raw material directly integrates into downstream manufacturing lines, supporting strict compliance and precise process requirements.

1. Active Pharmaceutical Ingredient (API) Intermediate for Neurological Agents

This building block plays a critical role in the multistep synthesis of several CNS (central nervous system) pharmaceutical compounds. Its enantiopure structure supports stereoselective chemical transformations required for next-generation antiepileptic and neuroprotective drugs. Manufacturers rely on batch traceability and controlled environments to ensure API grade output. Our raw material is directly charged during the amide-bond forming steps, influencing downstream yield and isomeric purity.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for APIs
• US FDA 21 CFR Part 211
• European Pharmacopoeia (EP) monograph compliance for relevant CNS APIs
• USP <823>, GMP Annex 1 requirements

Typical usage ratio

• 0.12 to 0.28 molar equivalents per target API molecule, adjusted according to route selectivity and lot-to-lot purity assessments

Downstream process integration

• Direct input in chiral amide coupling, usually following N-Boc deprotection and activation with HATU or EDC in DMF or DCM at 0–5°C, monitored by HPLC until conversion completion

Final product types

• (R)-4-Substituted GABA analogues (e.g., fluoro-derivatives used in CNS therapies)
• Anticonvulsant preclinical candidates
• Neuroprotective drug intermediates
• Reference standards for certified pharmaceutical testing labs

2. Custom Peptide Synthesis for Drug Discovery

This protected amino acid derivative introduces specific stereochemistry and fluoroaromatic characteristics into peptide chains. Peptide synthesis facilities use it for solid-phase and solution-phase assembly of chemically modified peptides aimed at enhancing receptor selectivity and metabolic stability. It enters workflows at the Fmoc/Boc-protected amino acid incorporation stage for development of proprietary peptidomimetics.

Industry compliance standards

• ICH Q11 Development and Manufacture of Drug Substances
• ISO 9001:2015 for peptide manufacturing
• cGMP guidelines for investigational and clinical peptide batches (FDA, EMA)
• Synthetic peptide submission standards per USP <1047>

Typical usage ratio

• Equivalent to 1 residue per target peptide chain segment; typically 3–8% by mass of the full peptide batch, based on desired sequence density and chain length

Downstream process integration

• Coupling at amino acid elongation cycle on resin using coupling reagents (e.g., HBTU, DIC) at 0.90–1.05 molar ratio per cycle, followed by Boc deprotection under acidolytic conditions before further elongation or cleavage from resin

Final product types

• Fluorinated peptidomimetics for CNS targeting
• Bioactive peptide libraries for pharmaceutical screening
• Modified peptides for preclinical DMPK (drug metabolism/pharmacokinetics) studies
• Research-grade custom peptides for biotech start-ups

3. Chiral Auxiliary in Asymmetric Organic Synthesis

R&D and production sites focused on complex molecule synthesis use Boc-(R)-3-Amino-4-(4-Fluoro-Phenyl)-Butyric Acid as an enantiomerically pure precursor or as a chiral auxiliary. Its incorporation in stereoselective catalytic transformations is essential for maintaining integrity in the production of single-isomer bioactive intermediates and advanced fine chemicals.

Industry compliance standards

• ISO 9001:2015 for specialty chemical synthesis
• REACH compliance for specialty chemicals in EU
• ICH Q11 for control of starting materials in pharmaceutical synthesis
• China GB/T 19001-2016/ISO 9001:2015 redundancy checks for reference standards

Typical usage ratio

• 0.10 to 0.22 equivalents per chiral center generated, depending on required optical rotation and selectivity targets

Downstream process integration

• Inserted in the synthesis route before key asymmetric cyclization or alkylation reactions, typically after Boc protection and fluorination steps, followed by in-line removal under mild acid and chromatographic purification

Final product types

• Single enantiomer intermediates for specialty APIs
• Chiral auxiliaries for asymmetric catalysis
• Chemical reference standards for analytical QA/QC labs

4. Building Block in Fluorinated Fine Chemicals

Chemical manufacturers requiring fluorinated aromatic or aliphatic intermediates utilize this compound for further downstream fluorination, amide, or esterification steps. Its protected amine functionality supports multistep synthesis in plant-scale production of high-performance organic chemicals, with quality controls set at each batch stage.

Industry compliance standards

• REACH-registration for importation and intermediate use
• ISO 14001:2015 for environmental management
• Customs and Excise compliance for hazardous raw material use
• Internal manufacturing SOPs validated under cGMP for high-purity intermediates

Typical usage ratio

• 6% to 15% by mass of overall batch, optimized according to the molar demand of downstream steps and the purity specification required for fine chemical end-uses

Downstream process integration

• Charged post-initial fluorination and protection, before ester/amide coupling; purification by crystallization or column chromatography is carried out after key conversions to ensure contaminant levels below detection

Final product types

• Fluorinated pharmaceutical intermediates
• Advanced organic electronic materials
• Custom-synthesized fine chemical blocks for biotech and electronics

5. Ingredient for High-Throughput Compound Library Synthesis

Combinatorial chemistry facilities employ Boc-(R)-3-Amino-4-(4-Fluoro-Phenyl)-Butyric Acid in automated synthesis of chemical libraries for pharmaceutical screening programs. It sources structural diversity due to its chiral and fluoroaromatic features, essential in hit-to-lead optimization pipelines. Process chemists vary loading profiles based on plate or batch scale, always integrating real-time QC analytics.

Industry compliance standards

• ISO 13485:2016 for research-grade chemical manufacturing
• US EPA rules on waste minimization for combinatorial processes
• Internal quality programs for medicinal chemistry compounds
• NIH chemical safety protocol for screening materials

Typical usage ratio

• Up to 1 compound per library entity (1–3% by mass relative to total library mass), adjusted for desired compound pool complexity and screening requirements

Downstream process integration

• Loaded as an individual building block in automated plate-based liquid handling or batch reactors; feeding sequence is adjusted to maximize diversity output during microplate parallel synthesis

Final product types

• Small molecule screening libraries for pharmaceutical R&D
• Lead-like compound sets for high-throughput screening platforms
• Medicinal chemistry discovery sets for academic research partners